| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-07-05 |
| タイトル |
|
|
タイトル |
A COMPARISON OF THE THERAPEUTIC EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION AND COMBINATION THERAPY WITH TRANSARTERIAL CHEMOEMBOLIZATION PLUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
TACE |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sorafenib |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
combination therapy |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
unresectable HCC |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.20569/00003585 |
|
ID登録タイプ |
JaLC |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
SUGIMOTO, Yuko
SATO, Wataru
SUZUKI, Toshiaki
MATSUZAWA, Hisanori
MINAMI, Shinichiro
TAKAHASHI, Kenichi
ARATA, Suguru
SHIBUYA, Tomomi
CHIBA, Mitsuru
DOHMEN, Takahiro
OHSHIMA, Shigetoshi
TOZAWA, Tomoki
ISHIYAMA, Koichi
Hashimoto, Manabu
GOTO, Takashi
IIJIMA, Katsunori
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
[Background and Aims] The combination therapy of transarterial chemoembolization (TACE) plus sorafenib has been applied for unresectable hepatocellular carcinoma (HCC). However, its efficacy remains controversial, possibly due to the timing of the initiation of sorafenib treatment. We evaluated the efficacy of this combination therapy when sorafenib treatment was initiated soon after the patient recovered from the adverse events due to the initial TACE procedure. [Methods] This was a retrospective study at a single hospital. Twenty-three unresectable HCC cases who exceeded the up-to-seven criteria but who showed no major vascular invasion or extrahepatic metastasis were enrolled in this study. The patients were classified into two groups : Group C (n=7) received combination therapy ; Group T (n=16) received TACE as the sole therapy. The time-to-tumor progression (TTP) and overall survival (OS) of the two groups were compared. [Results] The median TTP in Groups C and T was 1,737 days and 422 days, respectively (p < 0.05). The median survival time (MST) after the initiation of each therapy in Groups C and T was 1,780 days and 371 days, respectively (p < 0.05). [Conclusion] The TTP and OS of patients with unresectable HCC who received TACE plus sorafenib (administered soon after the initial TACE procedure) were superior to those in patients who received TACE alone. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
ja : 秋田医学
en : Akita journal of medicine
巻 44,
号 3/4,
p. 87-92,
発行日 2018-03
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0386-6106 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00009294 |
| 出版者 |
|
|
出版者 |
秋田医学会 |
|
言語 |
ja |
akitai44_3_4(87) (617.9 kB)
